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ORIGINAL ARTICLE
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Italy; bDepartment of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Sidney Kimmel Medical College of Thomas
Jefferson University, Philadelphia, PA, USA
ABSTRACT
Objective: To assess the risk of preeclampsia in women who underwent chorionic villus sam-
pling (CVS).
Study design: This is a retrospective, single-center, cohort study. All consecutive singleton gesta-
tions who underwent chorionic villus sampling from January 2014 to January 2016 were
included in the study. The primary outcome was the incidence of preeclampsia. Subgroup ana-
lysis in women with beta thalassemic trait was performed. Logistic regression, presented as
adjusted odds ratio (aOR) with the 95% of confidence interval (CI), was performed.
Results: Five hundred forty-seven women who underwent CVS, and 1532 women who did not
were analyzed. Women who underwent CVS had a significantly lower risk of preeclampsia (4.4
versus 8.0%; aOR 0.53, 95%CI 0.34–0.83), and late-onset preeclampsia (3.3 versus 6.1%; aOR 0.52,
95%CI 0.31–0.87). No statistically significant differences were found in preeclampsia with severe
features, early-onset preeclampsia, and preterm birth (PTB). Women who underwent CVS due to
thalassemic trait had a lower incidence of preeclampsia compare to those women who did not
undergo CVS (3.3 versus 8.0%; aOR 0.39, 95%CI 0.14–0.87), while no differences were found com-
paring women who underwent CVS due to thalassemic trait with women who underwent CVS
due to other reasons.
Conclusions: Women who underwent first trimester CVS had a lower risk of preeclampsia com-
pared to those who did not.
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Introduction
Preeclampsia is a leading cause of maternal and
neonatal mortality and morbidity, complicating up to
5–10% of all pregnancies [1]. The etiology of pree-
clampsia is unknown [1], as well as the associated
risk factors [1–10]. Although much of the literature
has focused on the degree of trophoblastic invasion
by the placenta, also local environmental factors and
iron deficiency are associated [11]. Placental disrup-
tion during early pregnancy may enhance abnormal
placentation, and invasive prenatal diagnosis, includ-
ing chorionic villus sampling (CVS) has been
suggested to increase the risk of hypertensive
complications and preeclampsia in some studies,
while others showed a decrease in these complica-
tions [12–14].
Thus, the aim of this study was to estimate the risk
of preeclampsia after first trimester CVS.
Materials and methods
This was a retrospective cohort study. Clinical records
of all consecutive singleton pregnancies who under-
went CVS at the University of Naples “Federico II”
(Naples, Italy) from January 2014 to August 2016 were
collected in a dedicated merged database. Women
with multiple gestations, and those with chronic
hypertension were excluded.
In our institution, routine procedure during the
study period was that CVS was performed by MFM
attendings transabdominally using a single-needle
technique under ultrasound guidance between 12 and
15 weeks of gestation with a 20- or 22-ga needle.
The primary outcome was the incidence of pree-
clampsia [15]. The secondary outcomes were intrauter-
ine growth restriction (i.e. ultrasound estimated fetal
weight <10th centile), preeclampsia with severe fea-
tures, early-onset (i.e. preeclampsia requiring delivery
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before 34 weeks) and late-onset preeclampsia (i.e. pre-
eclampsia requiring delivery at or after 34 weeks), and
preterm birth (PTB) <37 weeks. The comparison group
included women with singleton gestations who did
not undergo CVS. Comparison group included all con-
secutive singleton gestations without chronic hyper-
tension referred to our Department in the same period
(January 2014 to August 2016).
Subgroup analysis for the primary outcome (i.e. inci-
dence of preeclampsia) in women who underwent CVS
due to beta thalassemic trait was performed.
Diagnosis and management of preeclampsia and
preeclampsia with severe features were based on 2013
ACOG guidelines [15]. Preeclampsia (i.e. preeclampsia
without severe features) was defined as a blood pres-
sure elevation (140/90 on two occasions 4 h apart or
160/110 once), after 20 weeks of gestation, with pro-
teinuria (300mg on 24-h protein or >0.3 protein/cre-
atinine ratio) or any of the following if proteinuria not
present: platelets <100,000; creatinine >1.1 (or dou-
bling of creatinine in absence of other renal disease);
doubled of AST or ALT. Preeclampsia with severe fea-
tures was defined as preeclampsia with any of the fol-
lowing: blood pressure 160/110 4 h apart on bed
rest (unless on antihypertensive); platelets <100,000;
doubling of AST or ALT; creatinine >1.1 (or doubling
of creatinine in absence of other renal disease); pul-
monary edema; new cerebral or visual disturbances.
Statistical analysis was performed using statistical
package for social sciences (SPSS) v. 19.0 (IBM Inc,
Armonk, NY). Data are shown as means ± SD, or as
number (percentage). Univariate comparisons of
dichotomous data were performed with the use of the
chi-square or Fisher’s exact test. Comparisons between
groups were performed with the use of the t-test to
test group means with SD. Primary and secondary out-
comes were estimated with multivariate analyses.
Logistic regression, presented as unadjusted odds
ratio (crude odds ratio (OR)) or adjusted odds ratio
(aOR) with the 95% of confidence interval (CI), was
performed. Adjusted analysis was performed to correct
data for relevant baseline characteristics. Adjusted ana-
lysis was performed including all potentially relevant
baseline characteristics to the model as covariates.
We calculated two sided p-values. A p-value < .05
was considered to indicated statistical significance.
Results
Five hundred forty-seven women who underwent CVS,
and 1532 women who did not were analyzed (Figure 1).
Characteristics of women are shown in Table 1. All
women were singleton pregnancies without chronic
hypertension.
Table 2 shows primary and secondary outcomes.
Women who underwent CVS had a significantly lower
risk of preeclampsia (4.4 vs. 8.0%; aOR 0.53, 95%CI
0.34–0.83), and late-onset preeclampsia (3.3 vs. 6.1%;
aOR 0.52, 95%CI 0.31–0.87). No statistically significant
differences were found in preeclampsia with severe
features, early-onset preeclampsia, and PTB.
Women who underwent CVS due to thalassemic
trait had a lower incidence of preeclampsia compared
to those women who did not undergo CVS (3.3 vs.
Figure 1. Study flow chart.
Table 1. Characteristics of the included women.
CVS
n¼ 547
Control group
n¼ 1532 p value
Age
Mean ± SD (years) 27.4 ± 4.5 28.2 ± 9.3 .11
Nulliparous n (%) 450 (82.3%) 1200 (72.3%) .17
Ethnicity
Caucasian n (%) 498 (91.0%) 1379 (90.0%) .14
NonCaucasian n (%) 49 (9.0%) 153 (10.0%)
BMI
Mean ± SD (kg/m2) 25.3 ± 12.4 25.8 ± 11.2 .74
Smoking n (%) 57 (10.4%) 150 (9.8%) .47
Diabetes mellitus (including
GDM) n (%)
28 (5.1%) 80 (5.2%) .93
Data are presented as number (percentage) or as mean± stan-
dard deviation.
SD: standard deviation; BMI: body mass index; CVS: chorionic villus sam-
pling; GDM: gestational diabetes mellitus.
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8.0%; aOR 0.39, 95%CI 0.14–0.87), while no differences
were found comparing women who underwent CVS
due to thalassemic trait with women who underwent
CVS due to other reasons (Table 3).
Discussion
Main findings
This study, including 547 women who underwent CVS,
and 1532 women who did not, showed that women
who underwent first trimester CVS had lower risk of
preeclampsia.
Comparison with the prior literature
Our data concur with prior studies, but are at odds
with others. Sotiriadis et al. showed that CVS was not
associated with fetal growth impairment, while it was
associated with a decrease in the rate of preeclampsia
[16]. Silver et al. concluded that the focal disruption of
the placenta in the first trimester following 13–14
weeks CVS may increase the risk of hypertension and
preeclampsia [12]. Cederholm et al. in a population-
based study showed that among women aged 35–49
years, amniocentesis and CVS were not associated
with important adverse outcomes, such as preeclamp-
sia or abruption [13].
Strengths and limitations
Our study has several strengths. The number of
women included was high. We performed subgroup
analysis in women with beta thalassaemic trait to
explore the role of anemia to the developing of pree-
clampsia. We used the new ACOG guidelines for the
diagnosis and management of preeclampsia. However,
the retrospective approach of the study is the major
shortcoming. Because of its retrospective nature, it
was not possible to separate the importance of CVS
versus possible other confounders. Because this was
not a randomized comparison, the findings were
subjective to bias. We evaluated the effect of only
transabdominal CVS as a technique, and therefore the
possible effect of other CVS technical aspects (eg
trancervical CVS) was not studied.
Implications
The possible association between CVS and placenta
related complications was first highlighted by Silver
et al. [12]. They concluded that the focal disruption of
the placenta in the first trimester following 13–14
weeks CVS may increase the risk of hypertension and
preeclampsia. However, other published evidence
showed that it is very likely that first trimester pla-
centa is compliant enough to overcome the damage
cause by CVS. Our study provides evidence that this
overcome may decrease the risk of preeclampsia by
Table 2. Primary and secondary outcomes.
CVS n¼ 547 Control group n¼ 1532 Crude OR (95%CI) aOR (95%CI)a
Preeclampsia 24 (4.4%) 122 (8.0%) 0.48 (0.44–0.74) 0.53 (0.34–0.83)
Preeclampsia with severe features 7 (1.3%) 33 (2.2%) 0.52 (0.34–0.98) 0.59 (0.26–1.34)
Early-onset preeclampsia 6 (1.1%) 28 (1.8%) 0.54 (0.34–1.12) 0.60 (0.25–1.45)
Late-onset preeclampsia 18 (3.3%) 94 (6.1%) 0.50 (0.41–0.79) 0.52 (0.31–0.87)
PTB <37 weeks 41 (7.5%) 133 (8.7%) 0.82 (0.60–0.99) 0.85 (0.59–1.23)
IUGR <10th 57 (10.4%) 300 (19.6%) 0.53 (0.41–0.69) 0.56 (0.40–0.72)
IUGT <5th 31 (5.7%) 105 (6.9%) 0.83 (0.56–1.22) 0.85 (0.50–1.37)
Data are presented as number (percentage) or as mean ± standard deviation.
SD: standard deviation; BMI: body mass index; CVS: chorionic villus sampling; GDM: gestational diabetes mellitus; OR:
odds ratio; CI: confidence interval; aOR: adjusted odds ratio; IUGR: intrauterine growth restriction; PTB: preterm birth.
aAdjusted for all variables reported in Table 1.
Boldface data, statistically significant.
Table 3. Primary outcome in subgroup analyses.
CVS thalasemic trait
n¼ 123
CVS other reasons
n¼ 424 Crude OR (95%CI) aOR (95%CI)a
CVS for thalassemic trait versus CVS for other reasons
Preeclampsia 4 (3.3%) 20 (4.7%) 0.62 (0.34–1.42) 0.68 (0.23–2.03)
n¼ 1532
CVS for thalassemic trait versus no CVS
Preeclampsia 4 (3.3%) 122 (8.0%) 0.34 (0.33–0.74) 0.39 (0.14–0.87)
Data are presented as number (percentage).
OR: odds ratio; CI: confidence interval; aOR: adjusted odds ratio; CVS: chorionic villus sampling.
aAdjusted for all variables reported in Table 1.
Boldface data, statistically significant.
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better reconstruction of the villi; a local injury of
trophoblast because the needle’s passage in the chor-
ion may activates mechanisms of remodeling and
reorganization of the architecture of chorionic plate
with increased trophoblast invasion into spiral arteries.
In a past letter [17], we described a lower rate of pree-
clampsia in women who underwent CVS because of
thalassaemic trait; the hypothesis was a sum of two
effects: (1) the mechanic effect with the repair of villi
after the injury of the chorion, (2) the hypoxemic
effect induced by maternal anemia. Tissue hypoxia
induced by maternal anemia may stimulate an adap-
tive response designed to increase oxygen transfer
towards the placenta. In pregnancies with a low
maternal hemoglobin concentration, trophoblast inva-
sion into the spiral arteries is increased leading to
increased spiral artery lumina [18]. These mechanisms
of compensation may explain the lower rate of pree-
clampsia in our population even if the mayor effect
seems to be the mechanic one since no differences of
incidence of PE were found comparing women who
underwent CVS due to thalassemic trait with women
who underwent CVS due to other reasons. However,
it is important to highlight that most women with
beta-thalassemia may not have a degree of anemia
that would translate in a hypoxia-induced improved
trophoblast invasion.
Conclusions
In summary, women who underwent first trimester
CVS had a lower risk of preeclampsia compared to
those who did not.
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